Literature DB >> 27398287

Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Rebecca C Hoesli1, Jeffrey S Moyer1.   

Abstract

Head and neck squamous cell carcinoma has been found to be an immunosuppressive malignancy, with many defects in the host immune system contributing to the progression of disease. A greater understanding of these defects has lead to the identification and investigation of new therapeutic strategies, targeting immune system dysfunction in an effort to improve the outcomes of this disease. This article provides a brief review of the knowledge regarding the immune defects present in head and neck cancer, as well as a review of the current therapeutic strategies being investigated for use.

Entities:  

Keywords:  head and neck cancer; immunology; squamous cell carcinoma

Year:  2016        PMID： 27398287      PMCID： PMC4936409          DOI： 10.1007/s40496-016-0082-2

Source DB:  PubMed          Journal:  Curr Oral Health Rep


  88 in total

1.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Authors:  Gregory T Wolf; Willard E Fee; Robert W Dolan; Jeffrey S Moyer; Michael J Kaplan; Paul M Spring; James Suen; Daniel E Kenady; Jason G Newman; William R Carroll; M Boyd Gillespie; Scott M Freeman; Lorraine Baltzer; Terry D Kirkley; Harvey J Brandwein; John W Hadden
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

2.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

3.  Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up.

Authors:  Jose A Seixas-Silva; Thomas Richards; Fadlo R Khuri; H Samuel Wieand; Ed Kim; Barbara Murphy; Marites Francisco; Waun Ki Hong; Dong M Shin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2005-04

Review 4.  Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.

Authors:  Mark S Swanson; Uttam K Sinha
Journal:  Oral Oncol       Date:  2014-10-28       Impact factor: 5.337

5.  Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

Review 7.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

Authors:  Robert L Ferris; Elizabeth M Jaffee; Soldano Ferrone
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

10.  Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx.

Authors:  Antonella De Stefani; Guido Forni; Riccardo Ragona; Giovanni Cavallo; Mario Bussi; Antonio Usai; Fausto Badellino; Giorgio Cortesina
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860
View more
  3 in total

1.  Construction of a Ferroptosis-Related Gene Signature for Head and Neck Squamous Cell Carcinoma Prognosis Prediction.

Authors:  Qun Li; Yangli Jin; Zhisen Shen; Huigao Liu; Yi Shen; Zhenhua Wu
Journal:  Int J Gen Med       Date:  2021-12-21

2.  Role of Nrf2 signaling pathway in the radiation tolerance of patients with head and neck squamous cell carcinoma: an in vivo and in vitro study.

Authors:  Tao Wang; Peng Hu; Bo Li; Jun-Peng Zhang; Yu-Feng Cheng; Ye-Min Liang
Journal:  Onco Targets Ther       Date:  2017-03-23       Impact factor: 4.345

3.  Profiles of immune cell infiltration in head and neck squamous carcinoma.

Authors:  Bin Liang; Ye Tao; Tianjiao Wang
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.